Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian BioSciences Completes Pre-IND After FDA Comments

10/18/2021 | 07:55am EST

By Chris Wack

Enochian BioSciences Inc. Monday said it completed an investigator pre-investigational new drug process following receipt of written comments from the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies.

The company said the request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy. The patient subsequently stopped taking ART and received an innovative treatment developed by SRI.

Enochian BioSciences holds the exclusive license for the product.

The company said the patient's HIV infection blood levels were controlled more effectively for 365 consecutive days off ART using the SRI treatment compared to what had previously been achieved with ART.

Enochian shares rose 3% to $8.90 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

10-18-21 0754ET

All news about ENOCHIAN BIOSCIENCES, INC.
2021ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)
AQ
2021Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on P..
AQ
2021ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)
AQ
2021ENOCHIAN BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition a..
AQ
2021Enochian Biosciences, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
2021Amendment to Annual Report (Form 10-K/A)
PU
2021Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
2021ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
2021ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
2021Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -9,71x
Yield 2021 -
Capitalization 260 M 260 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,9%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.-31.69%260
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805